119 related articles for article (PubMed ID: 11007920)
1. The pharmacokinetics and pharmacodynamics of GW395058, a peptide agonist of the thrombopoietin receptor, in the dog, a large-animal model of chemotherapy-induced thrombocytopenia.
Case BC; Hauck ML; Yeager RL; Simkins AH; de Serres M; Schmith VD; Dillberger JE; Page RL
Stem Cells; 2000; 18(5):360-5. PubMed ID: 11007920
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and hematological effects of the PEGylated thrombopoietin peptide mimetic GW395058 in rats and monkeys after intravenous or subcutaneous administration.
de Serres M; Yeager RL; Dillberger JE; Lalonde G; Gardner GH; Rubens CA; Simkins AH; Sailstad JM; McNulty MJ; Woolley JL
Stem Cells; 1999; 17(6):316-26. PubMed ID: 10606160
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man.
de Serres M; Ellis B; Dillberger JE; Rudolph SK; Hutchins JT; Boytos CM; Weigl DL; DePrince RB
Stem Cells; 1999; 17(4):203-9. PubMed ID: 10437983
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects.
Samtani MN; Perez-Ruixo JJ; Brown KH; Cerneus D; Molloy CJ
J Clin Pharmacol; 2009 Mar; 49(3):336-50. PubMed ID: 19246731
[TBL] [Abstract][Full Text] [Related]
5. Hematologic and systemic toxicoses associated with carboplatin administration in cats.
Hahn KA; McEntee MF; Daniel GB; Legendre AM; Nolan ML
Am J Vet Res; 1997 Jun; 58(6):677-9. PubMed ID: 9185979
[TBL] [Abstract][Full Text] [Related]
6. [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor].
Bai CM; Xu GX; Zhao YQ; Han SM; Shan YD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):437-41. PubMed ID: 15379272
[TBL] [Abstract][Full Text] [Related]
7. PEG-rHuMGDF ameliorates thrombocytopenia in carboplatin-treated rats without inducing myelofibrosis.
Ide Y; Harada K; Imai A; Yanagida M
Int J Hematol; 1999 Aug; 70(2):91-6. PubMed ID: 10497847
[TBL] [Abstract][Full Text] [Related]
8. Thrombopoietin-induced signal transduction and potentiation of platelet activation.
Oda A; Miyakawa Y; Druker BJ; Ozaki K; Ohashi H; Kato T; Miyazaki H; Handa M; Ikebuchi K; Ikeda Y
Thromb Haemost; 1999 Aug; 82(2):377-84. PubMed ID: 10605727
[No Abstract] [Full Text] [Related]
9. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand.
Wang B; Nichol JL; Sullivan JT
Clin Pharmacol Ther; 2004 Dec; 76(6):628-38. PubMed ID: 15592334
[TBL] [Abstract][Full Text] [Related]
10. [The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia].
Bai CM; Zou XY; Zhao YQ; Han SM; Shan YD;
Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):397-400. PubMed ID: 15061993
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study.
Wolff SN; Herzig R; Lynch J; Ericson SG; Greer JP; Stein R; Goodman S; Benyunes MC; Ashby M; Jones DV; Fay J
Bone Marrow Transplant; 2001 Feb; 27(3):261-8. PubMed ID: 11277173
[TBL] [Abstract][Full Text] [Related]
12. Peptide agonists of the thrombopoietin receptor.
Dower WJ; Cwirla SE; Balasubramanian P; Schatz PJ; Baccanari DP; Barrett RW
Stem Cells; 1998; 16 Suppl 2():21-9. PubMed ID: 11012174
[TBL] [Abstract][Full Text] [Related]
13. [Clinical application of platelet hematopoiesis factor, thrombopoietin(c-Mp1ligand)].
Fujimoto K; Kawakita M
Nihon Naika Gakkai Zasshi; 1996 Jun; 85(6):850-6. PubMed ID: 8753051
[No Abstract] [Full Text] [Related]
14. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
Cairo MS; Davenport V; Bessmertny O; Goldman SC; Berg SL; Kreissman SG; Laver J; Shen V; Secola R; van de Ven C; Reaman GH
Br J Haematol; 2005 Jan; 128(1):49-58. PubMed ID: 15606549
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice.
Krzyzanski W; Perez-Ruixo JJ; Harrold J
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):709-20. PubMed ID: 26341875
[TBL] [Abstract][Full Text] [Related]
17. Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman primates.
Schlerman FJ; Bree AG; Kaviani MD; Nagle SL; Donnelly LH; Mason LE; Schaub RG; Grupp SA; Goldman SJ
Stem Cells; 1996 Sep; 14(5):517-32. PubMed ID: 8888493
[TBL] [Abstract][Full Text] [Related]
18. Studies of the c-Mpl thrombopoietin receptor through gene disruption and activation.
Alexander WS; Roberts AW; Maurer AB; Nicola NA; Dunn AR; Metcalf D
Stem Cells; 1996; 14 Suppl 1():124-32. PubMed ID: 11012212
[TBL] [Abstract][Full Text] [Related]
19. Effects of lithium carbonate on carboplatin-induced thrombocytopenia in dogs.
Leclerc A; Abrams-Ogg AC; Kruth SA; Bienzle D
Am J Vet Res; 2010 May; 71(5):555-63. PubMed ID: 20433382
[TBL] [Abstract][Full Text] [Related]
20. Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: effect of schedule, dose, and route of administration.
Farese AM; Casey DB; Smith WG; Vigneulle RM; McKearn JP; MacVittie TJ
Stem Cells; 2001; 19(6):522-33. PubMed ID: 11713344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
